Chapter/Section Purchase

1 Study Coverage
1.1 Poxviridae Infections Drug Product Introduction
1.2 Market by Type
1.2.1 Global Poxviridae Infections Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 CJ-40011
1.2.3 24a
1.2.4 BA-368
1.2.5 Others
1.3 Market by Application
1.3.1 Global Poxviridae Infections Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Poxviridae Infections Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Poxviridae Infections Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Poxviridae Infections Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Poxviridae Infections Drug Sales by Region
2.4.1 Global Poxviridae Infections Drug Sales by Region (2017-2022)
2.4.2 Global Sales Poxviridae Infections Drug by Region (2023-2028)
2.5 Global Poxviridae Infections Drug Revenue by Region
2.5.1 Global Poxviridae Infections Drug Revenue by Region (2017-2022)
2.5.2 Global Poxviridae Infections Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Poxviridae Infections Drug Sales by Manufacturers
3.1.1 Global Top Poxviridae Infections Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Poxviridae Infections Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Poxviridae Infections Drug in 2021
3.2 Global Poxviridae Infections Drug Revenue by Manufacturers
3.2.1 Global Poxviridae Infections Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Poxviridae Infections Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Poxviridae Infections Drug Revenue in 2021
3.3 Global Poxviridae Infections Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Poxviridae Infections Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Poxviridae Infections Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Poxviridae Infections Drug Sales by Type
4.1.1 Global Poxviridae Infections Drug Historical Sales by Type (2017-2022)
4.1.2 Global Poxviridae Infections Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Poxviridae Infections Drug Sales Market Share by Type (2017-2028)
4.2 Global Poxviridae Infections Drug Revenue by Type
4.2.1 Global Poxviridae Infections Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Poxviridae Infections Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Poxviridae Infections Drug Revenue Market Share by Type (2017-2028)
4.3 Global Poxviridae Infections Drug Price by Type
4.3.1 Global Poxviridae Infections Drug Price by Type (2017-2022)
4.3.2 Global Poxviridae Infections Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Poxviridae Infections Drug Sales by Application
5.1.1 Global Poxviridae Infections Drug Historical Sales by Application (2017-2022)
5.1.2 Global Poxviridae Infections Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Poxviridae Infections Drug Sales Market Share by Application (2017-2028)
5.2 Global Poxviridae Infections Drug Revenue by Application
5.2.1 Global Poxviridae Infections Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Poxviridae Infections Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Poxviridae Infections Drug Revenue Market Share by Application (2017-2028)
5.3 Global Poxviridae Infections Drug Price by Application
5.3.1 Global Poxviridae Infections Drug Price by Application (2017-2022)
5.3.2 Global Poxviridae Infections Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Poxviridae Infections Drug Market Size by Type
6.1.1 North America Poxviridae Infections Drug Sales by Type (2017-2028)
6.1.2 North America Poxviridae Infections Drug Revenue by Type (2017-2028)
6.2 North America Poxviridae Infections Drug Market Size by Application
6.2.1 North America Poxviridae Infections Drug Sales by Application (2017-2028)
6.2.2 North America Poxviridae Infections Drug Revenue by Application (2017-2028)
6.3 North America Poxviridae Infections Drug Market Size by Country
6.3.1 North America Poxviridae Infections Drug Sales by Country (2017-2028)
6.3.2 North America Poxviridae Infections Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Poxviridae Infections Drug Market Size by Type
7.1.1 Europe Poxviridae Infections Drug Sales by Type (2017-2028)
7.1.2 Europe Poxviridae Infections Drug Revenue by Type (2017-2028)
7.2 Europe Poxviridae Infections Drug Market Size by Application
7.2.1 Europe Poxviridae Infections Drug Sales by Application (2017-2028)
7.2.2 Europe Poxviridae Infections Drug Revenue by Application (2017-2028)
7.3 Europe Poxviridae Infections Drug Market Size by Country
7.3.1 Europe Poxviridae Infections Drug Sales by Country (2017-2028)
7.3.2 Europe Poxviridae Infections Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Poxviridae Infections Drug Market Size by Type
8.1.1 Asia Pacific Poxviridae Infections Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Poxviridae Infections Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Poxviridae Infections Drug Market Size by Application
8.2.1 Asia Pacific Poxviridae Infections Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Poxviridae Infections Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Poxviridae Infections Drug Market Size by Region
8.3.1 Asia Pacific Poxviridae Infections Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Poxviridae Infections Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Poxviridae Infections Drug Market Size by Type
9.1.1 Latin America Poxviridae Infections Drug Sales by Type (2017-2028)
9.1.2 Latin America Poxviridae Infections Drug Revenue by Type (2017-2028)
9.2 Latin America Poxviridae Infections Drug Market Size by Application
9.2.1 Latin America Poxviridae Infections Drug Sales by Application (2017-2028)
9.2.2 Latin America Poxviridae Infections Drug Revenue by Application (2017-2028)
9.3 Latin America Poxviridae Infections Drug Market Size by Country
9.3.1 Latin America Poxviridae Infections Drug Sales by Country (2017-2028)
9.3.2 Latin America Poxviridae Infections Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Poxviridae Infections Drug Market Size by Type
10.1.1 Middle East and Africa Poxviridae Infections Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Poxviridae Infections Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Poxviridae Infections Drug Market Size by Application
10.2.1 Middle East and Africa Poxviridae Infections Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Poxviridae Infections Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Poxviridae Infections Drug Market Size by Country
10.3.1 Middle East and Africa Poxviridae Infections Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Poxviridae Infections Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Bavarian Nordic A/S
11.1.1 Bavarian Nordic A/S Corporation Information
11.1.2 Bavarian Nordic A/S Overview
11.1.3 Bavarian Nordic A/S Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Bavarian Nordic A/S Poxviridae Infections Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bavarian Nordic A/S Recent Developments
11.2 BioFactura, Inc.
11.2.1 BioFactura, Inc. Corporation Information
11.2.2 BioFactura, Inc. Overview
11.2.3 BioFactura, Inc. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 BioFactura, Inc. Poxviridae Infections Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 BioFactura, Inc. Recent Developments
11.3 CEL-SCI Corporation
11.3.1 CEL-SCI Corporation Corporation Information
11.3.2 CEL-SCI Corporation Overview
11.3.3 CEL-SCI Corporation Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 CEL-SCI Corporation Poxviridae Infections Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 CEL-SCI Corporation Recent Developments
11.4 Chimerix, Inc.
11.4.1 Chimerix, Inc. Corporation Information
11.4.2 Chimerix, Inc. Overview
11.4.3 Chimerix, Inc. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Chimerix, Inc. Poxviridae Infections Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Chimerix, Inc. Recent Developments
11.5 China Biologic Products, Inc.
11.5.1 China Biologic Products, Inc. Corporation Information
11.5.2 China Biologic Products, Inc. Overview
11.5.3 China Biologic Products, Inc. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 China Biologic Products, Inc. Poxviridae Infections Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 China Biologic Products, Inc. Recent Developments
11.6 CJ HealthCare Corp.
11.6.1 CJ HealthCare Corp. Corporation Information
11.6.2 CJ HealthCare Corp. Overview
11.6.3 CJ HealthCare Corp. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 CJ HealthCare Corp. Poxviridae Infections Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 CJ HealthCare Corp. Recent Developments
11.7 EpiVax, Inc.
11.7.1 EpiVax, Inc. Corporation Information
11.7.2 EpiVax, Inc. Overview
11.7.3 EpiVax, Inc. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 EpiVax, Inc. Poxviridae Infections Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 EpiVax, Inc. Recent Developments
11.8 N & N Pharmaceuticals Inc.
11.8.1 N & N Pharmaceuticals Inc. Corporation Information
11.8.2 N & N Pharmaceuticals Inc. Overview
11.8.3 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 N & N Pharmaceuticals Inc. Recent Developments
11.9 SIGA Technologies, Inc.
11.9.1 SIGA Technologies, Inc. Corporation Information
11.9.2 SIGA Technologies, Inc. Overview
11.9.3 SIGA Technologies, Inc. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 SIGA Technologies, Inc. Poxviridae Infections Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 SIGA Technologies, Inc. Recent Developments
11.10 Takeda Pharmaceutical Company Limited
11.10.1 Takeda Pharmaceutical Company Limited Corporation Information
11.10.2 Takeda Pharmaceutical Company Limited Overview
11.10.3 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Takeda Pharmaceutical Company Limited Recent Developments
11.11 Tonix Pharmaceuticals Holding Corp.
11.11.1 Tonix Pharmaceuticals Holding Corp. Corporation Information
11.11.2 Tonix Pharmaceuticals Holding Corp. Overview
11.11.3 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Tonix Pharmaceuticals Holding Corp. Recent Developments
11.12 Verrica Pharmaceuticals Inc.
11.12.1 Verrica Pharmaceuticals Inc. Corporation Information
11.12.2 Verrica Pharmaceuticals Inc. Overview
11.12.3 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Verrica Pharmaceuticals Inc. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Poxviridae Infections Drug Industry Chain Analysis
12.2 Poxviridae Infections Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Poxviridae Infections Drug Production Mode & Process
12.4 Poxviridae Infections Drug Sales and Marketing
12.4.1 Poxviridae Infections Drug Sales Channels
12.4.2 Poxviridae Infections Drug Distributors
12.5 Poxviridae Infections Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Poxviridae Infections Drug Industry Trends
13.2 Poxviridae Infections Drug Market Drivers
13.3 Poxviridae Infections Drug Market Challenges
13.4 Poxviridae Infections Drug Market Restraints
14 Key Findings in The Global Poxviridae Infections Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer